Adolor Entereg NDA For Postoperative Ileus Slated For First Half 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adolor plans to submit an NDA for its postoperative ileus agent Entereg (alvimopan) in the first half of 2004.
You may also be interested in...
Entereg Documents Offer Detailed Insight Into REMS Review Process
GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product